ArticleJournal of thoracic disease2025
Characteristics of symptoms among outpatients following the discontinuation of the dynamic zero-COVID-19 policy in China: insights from an online nationwide cross-sectional survey in 2022.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Changes in Epidemiological Characteristics in Children withJournal of clinical medicine · 2026Article
- Positive rates ofFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: After the cessation of the dynamic zero-coronavirus disease 2019 (COVID-19) policy in China, a large number of people were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) without being hospitalized, but few studies investigated the symptoms of this population. In this study, we aimed to describe the symptom characteristics of this population and to provide information for further understanding of COVID-19. Methods: An online nationwide anonymous survey questionnaire on symptoms was conducted through WeChat to probe participants infected with SARS-CoV-2 between December 2022 and January 2023. In order to guarantee the promptness of data collection while maximizing the coverage of diverse populations, we opted for the convenient sampling method. Demographic information, incidence and severity of main symptoms, and vaccination status were collected in the questionnaire. Descriptive analysis was utilized to elucidate the epidemiological characteristics of the overall population; comparative analysis was conducted to highlight the differences in symptom variations among distinct subgroups. Results: A total of 4,836 valid questionnaires were collected, with 64.8% testing positive for COVID-19 and 35.2% exhibiting symptoms but not having undergone testing. Among the COVID-19-positive respondents, 64.3% (n=2,016) were female, with a median age of 39.0 (33.0, 47.0) years, and 95.8% (n=3,002) had received multiple vaccine doses. The prevalent comorbidities included allergic rhinitis (10.1%), hypertension (6.1%), and diabetes (3.5%). The most frequently reported symptoms were fever (n=2,941, 93.9%), fatigue (n=2,871, 91.6%), expectoration (n=2,847, 90.8%), nasal congestion (n=2,735, 87.2%), and myalgia (n=2,712, 86.5%). Vaccinated individuals, non-smokers, and males exhibited significantly higher rates of respiratory symptoms. Myalgia (35.3%), fatigue (31.5%), and sore throat (30.9%) were the symptoms with the highest incidence of severe occurrence, and this varied between age groups. Except for sneezing, age of 60 years or older was negatively correlated with severe manifestations for all symptoms. Conversely, smoking was positively associated with severe symptoms for nearly all conditions. Conclusions: The study highlights common systemic and respiratory symptoms among non-hospitalized COVID-19 patients in China, varying by gender, age, and underlying diseases. These findings are clinically important for early identification, diagnosis, treatment evaluation, and global management of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.